Display options
Cite
Argentiero A, Solimando AG, Krebs M, et al. Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. J Clin Med. 2020;9(5)doi: 10.3390/jcm9051594.
Argentiero, A., Solimando, A. G., Krebs, M., Leone, P., Susca, N., Brunetti, O., Racanelli, V., Vacca, A., & Silvestris, N. (2020). Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. Journal of clinical medicine, 9(5), . https://doi.org/10.3390/jcm9051594
Argentiero, Antonella, et al. "Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma." Journal of clinical medicine vol. 9,5 (2020). doi: https://doi.org/10.3390/jcm9051594
Argentiero A, Solimando AG, Krebs M, Leone P, Susca N, Brunetti O, Racanelli V, Vacca A, Silvestris N. Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. J Clin Med. 2020 May 24;9(5). doi: 10.3390/jcm9051594. PMID: 32456352; PMCID: PMC7291047.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2020 May 24;9(5). doi: 10.3390/jcm9051594.

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma.

Journal of clinical medicine

Antonella Argentiero, Antonio Giovanni Solimando, Markus Krebs, Patrizia Leone, Nicola Susca, Oronzo Brunetti, Vito Racanelli, Angelo Vacca, Nicola Silvestris

Affiliations

  1. Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy.
  2. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine 'G. Baccelli', University of Bari Medical School, 70124 Bari, Italy.
  3. Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
  4. Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
  5. Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.

PMID: 32456352 PMCID: PMC7291047 DOI: 10.3390/jcm9051594

Abstract

Although decision making strategy based on clinico-histopathological criteria is well established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems characterized by distinct genetic and molecular alterations, diverse clinical courses and potential specific therapeutic vulnerabilities. Given the plethora of drugs available, the subtype-tailored treatment to RCC subtype holds the potential to improve patient outcome, shrinking treatment-related morbidity and cost. The emerging knowledge of the molecular taxonomy of RCC is evolving, whilst the antiangiogenic and immunotherapy landscape maintains and reinforces their potential. Although several prognostic factors of survival in patients with RCC have been described, no reliable predictive biomarkers of treatment individual sensitivity or resistance have been identified. In this review, we summarize the available evidence able to prompt more precise and individualized patient selection in well-designed clinical trials, covering the unmet need of medical choices in the era of next-generation anti-angiogenesis and immunotherapy.

Keywords: angiogenesis; immune-checkpoint inhibitor; molecular subtypes; predictive factors; prognostic-biomarkers; renal cell carcinoma; tumor microenvironment

References

  1. J Drug Target. 2019 Jan;27(1):67-74 - PubMed
  2. Clin Cancer Res. 2019 Oct 15;25(20):6080-6088 - PubMed
  3. J Clin Oncol. 2012 Sep 20;30(27):3402-7 - PubMed
  4. Hum Pathol. 2001 Jun;32(6):590-5 - PubMed
  5. Eur Urol. 2009 Nov;56(5):786-93 - PubMed
  6. Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994 - PubMed
  7. Oncotarget. 2016 May 3;7(18):26866-78 - PubMed
  8. Lancet Oncol. 2015 Nov;16(15):1473-1482 - PubMed
  9. Target Oncol. 2018 Apr;13(2):205-216 - PubMed
  10. J Clin Med. 2019 Jul 09;8(7): - PubMed
  11. J Clin Oncol. 2014 Mar 10;32(8):760-7 - PubMed
  12. N Engl J Med. 2015 Nov 5;373(19):1803-13 - PubMed
  13. N Engl J Med. 2013 Aug 22;369(8):722-31 - PubMed
  14. Cell Rep. 2016 Mar 15;14(10):2476-89 - PubMed
  15. Br J Cancer. 2013 Mar 5;108(4):755-61 - PubMed
  16. JCI Insight. 2016 Jul 7;1(10):e86051 - PubMed
  17. Blood Rev. 2006 Nov;20(6):333-42 - PubMed
  18. Haematologica. 2018 Jan;103(1):116-125 - PubMed
  19. J Clin Oncol. 2010 Feb 20;28(6):1061-8 - PubMed
  20. Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):213-220 - PubMed
  21. Haematologica. 2020 Apr 30;: - PubMed
  22. J Urol. 1996 Feb;155(2):743-8 - PubMed
  23. PLoS One. 2013;8(2):e55911 - PubMed
  24. Curr Pharm Des. 2004;10(1):11-26 - PubMed
  25. Lancet Oncol. 2016 Jan;17(1):e4-5 - PubMed
  26. Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612 - PubMed
  27. J Clin Oncol. 2008 Aug 1;26(22):3743-8 - PubMed
  28. J Clin Oncol. 2017 Feb 20;35(6):591-597 - PubMed
  29. Hum Mol Genet. 1996 Sep;5(9):1333-8 - PubMed
  30. Nature. 2016 Nov 3;539(7627):112-117 - PubMed
  31. Eur J Cancer. 2018 May;94:115-125 - PubMed
  32. Ther Adv Med Oncol. 2020 Mar 18;12:1758835920907504 - PubMed
  33. Trends Pharmacol Sci. 2008 Jan;29(1):12-5 - PubMed
  34. J Clin Med. 2019 Nov 20;8(12): - PubMed
  35. Clin Cancer Res. 2011 Aug 15;17(16):5443-50 - PubMed
  36. J Clin Med. 2020 Mar 02;9(3): - PubMed
  37. N Engl J Med. 2012 Mar 8;366(10):883-892 - PubMed
  38. Lancet. 2019 Jun 15;393(10189):2404-2415 - PubMed
  39. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6282S-9S - PubMed
  40. Nat Rev Urol. 2019 Sep;16(9):539-552 - PubMed
  41. PLoS One. 2013 Dec 30;8(12):e83026 - PubMed
  42. Acta Oncol. 2018 Apr;57(4):498-508 - PubMed
  43. J Clin Oncol. 1999 Aug;17(8):2530-40 - PubMed
  44. Int J Mol Sci. 2017 Nov 22;18(11): - PubMed
  45. Clin Cancer Res. 1999 Aug;5(8):2185-91 - PubMed
  46. J Clin Oncol. 2009 Dec 1;27(34):5794-9 - PubMed
  47. Toxicon. 2017 Feb;126:38-46 - PubMed
  48. N Engl J Med. 2019 Mar 21;380(12):1116-1127 - PubMed
  49. Cancers (Basel). 2019 Jul 04;11(7): - PubMed
  50. J Clin Med. 2020 Mar 28;9(4): - PubMed
  51. Front Cell Dev Biol. 2019 Apr 24;7:60 - PubMed
  52. Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):334-42 - PubMed
  53. Nature. 2003 Sep 18;425(6955):247-8 - PubMed
  54. Int J Oncol. 2016 Sep;49(3):1155-63 - PubMed
  55. Genes Cancer. 2010 Feb 1;1(2):152-163 - PubMed
  56. Nat Rev Cancer. 2008 Aug;8(8):592-603 - PubMed
  57. J Urol. 2008 Sep;180(3):860-5; discussion 865-6 - PubMed
  58. PLoS One. 2018 May 22;13(5):e0197035 - PubMed
  59. Cancer Discov. 2019 Oct;9(10):1349-1357 - PubMed
  60. J Urol. 2009 Sep;182(3):844-53 - PubMed
  61. Eur Urol. 2014 Nov;66(5):936-48 - PubMed
  62. Oncotarget. 2017 Jan 3;8(1):1204-1212 - PubMed
  63. Lancet Oncol. 2018 Dec;19(12):1688-1698 - PubMed
  64. Curr Cancer Drug Targets. 2012 Jul;12(6):693-702 - PubMed
  65. Int J Mol Sci. 2017 Nov 27;18(12): - PubMed
  66. J Pathol. 2019 Feb;247(2):241-253 - PubMed
  67. Neoplasia. 2018 Jun;20(6):610-620 - PubMed
  68. Microvasc Res. 2007 Sep-Nov;74(2-3):172-83 - PubMed
  69. N Engl J Med. 2018 Apr 05;378(14):1277-1290 - PubMed
  70. Lancet Oncol. 2011 Nov;12(12):1143-50 - PubMed
  71. Cancer Discov. 2019 Apr;9(4):510-525 - PubMed
  72. Eur Urol. 2011 May;59(5):721-30 - PubMed
  73. Lancet Oncol. 2012 Aug;13(8):827-37 - PubMed
  74. Cell Rep. 2018 Apr 3;23(1):313-326.e5 - PubMed
  75. Cancer. 2010 Sep 15;116(18):4256-65 - PubMed
  76. Eur Urol. 2017 Feb;71(2):204-209 - PubMed
  77. Oncoimmunology. 2018 Oct 22;8(1):e1486949 - PubMed
  78. Nat Rev Clin Oncol. 2016 Mar;13(3):143-58 - PubMed
  79. Lancet Oncol. 2013 Feb;14(2):159-167 - PubMed
  80. Sci Rep. 2015 May 18;5:10328 - PubMed
  81. Cancer. 2012 Apr 1;118(7):1946-54 - PubMed
  82. N Engl J Med. 2007 Jan 11;356(2):115-24 - PubMed
  83. Mol Ther. 2015 Nov;23(11):1748-1758 - PubMed
  84. Am J Surg Pathol. 1982 Oct;6(7):655-63 - PubMed
  85. Nature. 2013 Jul 4;499(7456):43-9 - PubMed
  86. J Urol. 2010 May;183(5):1708-13 - PubMed
  87. Medicina (Kaunas). 2019 Oct 21;55(10): - PubMed
  88. Cancer J. 2013 Jul-Aug;19(4):353-64 - PubMed
  89. Genome Med. 2011 Dec 30;3(12):79 - PubMed
  90. Oncotarget. 2017 Feb 21;8(8):13979-13985 - PubMed
  91. Br J Haematol. 2008 Dec;143(5):622-31 - PubMed
  92. Cancer. 2007 Mar 1;109(5):868-74 - PubMed
  93. Cancers (Basel). 2019 Dec 04;11(12): - PubMed
  94. N Engl J Med. 2019 Mar 21;380(12):1103-1115 - PubMed
  95. Urol Oncol. 2019 Jan;37(1):78-85 - PubMed
  96. BJU Int. 2010 Sep;106(6):772-8 - PubMed
  97. J Natl Cancer Inst. 2017 Oct 1;109(10): - PubMed
  98. J Clin Oncol. 2008 Nov 20;26(33):5422-8 - PubMed
  99. Biosci Trends. 2017 May 23;11(2):214-220 - PubMed
  100. Cancer Res. 1988 Dec 15;48(24 Pt 1):7310-3 - PubMed
  101. Lancet Oncol. 2015 Mar;16(3):293-300 - PubMed
  102. JAMA Oncol. 2019 Sep 5;: - PubMed
  103. Am J Surg Pathol. 2013 Oct;37(10):1490-504 - PubMed
  104. Br J Cancer. 2017 Aug 8;117(4):478-484 - PubMed
  105. Eur Urol. 2018 Oct;74(4):474-480 - PubMed
  106. Cancer Res. 1992 Jan 15;52(2):348-56 - PubMed
  107. Int J Mol Sci. 2020 Apr 27;21(9): - PubMed
  108. Tumori. 2018 Dec;104(6):476-479 - PubMed
  109. Clin Cancer Res. 2014 Apr 1;20(7):1955-64 - PubMed
  110. World J Urol. 2011 Jun;29(3):367-73 - PubMed
  111. Lancet Oncol. 2019 Apr;20(4):581-590 - PubMed
  112. Front Genet. 2019 Apr 24;10:320 - PubMed
  113. Angiogenesis. 2002;5(1-2):75-80 - PubMed
  114. N Engl J Med. 2007 May 31;356(22):2271-81 - PubMed
  115. Lancet Oncol. 2013 Feb;14(2):141-8 - PubMed
  116. Oncologist. 2019 Nov;24(11):1497-1501 - PubMed
  117. Front Oncol. 2019 Jun 14;9:490 - PubMed
  118. Front Oncol. 2019 Dec 11;9:1400 - PubMed
  119. Lancet Oncol. 2016 Jul;17(7):917-927 - PubMed
  120. BMC Cancer. 2010 Dec 31;10:695 - PubMed
  121. Lancet. 2011 Dec 3;378(9807):1931-9 - PubMed
  122. Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50 - PubMed
  123. J Exp Clin Cancer Res. 2015 Feb 05;34:10 - PubMed
  124. Nat Med. 2018 Jun;24(6):749-757 - PubMed
  125. J Clin Oncol. 2002 Jan 1;20(1):289-96 - PubMed
  126. Eur Urol. 2020 Apr;77(4):449-453 - PubMed
  127. Angiogenesis. 2013 Jan;16(1):181-94 - PubMed
  128. Cancers (Basel). 2019 Dec 19;12(1): - PubMed
  129. Cancer. 2013 Apr 15;119(8):1547-54 - PubMed
  130. Lancet Oncol. 2019 Oct;20(10):1370-1385 - PubMed
  131. Am J Clin Pathol. 2012 May;137(5):761-8 - PubMed
  132. Oncotarget. 2016 Sep 13;7(37):60698-60711 - PubMed
  133. Int J Oncol. 2009 Jul;35(1):109-14 - PubMed
  134. Lancet Oncol. 2015 Jun;16(6):676-85 - PubMed
  135. Science. 2018 Aug 10;361(6402):594-599 - PubMed
  136. Nat Genet. 2012 Jun 10;44(7):751-9 - PubMed
  137. J Clin Oncol. 2009 Jul 10;27(20):3312-8 - PubMed
  138. Nihon Ronen Igakkai Zasshi. 1992 Feb;29(2):123-8 - PubMed
  139. Breast Cancer Res. 2016 Aug 11;18(1):84 - PubMed
  140. Medicina (Kaunas). 2019 Oct 17;55(10): - PubMed

Publication Types

Grant support